- €7.65bn
- €18.65bn
- €7.52bn
Brief: Grifols Says It Has Decided To Initiate A Process To Evaluate A Potential US IPO Of A Portion Of Shares Of Its Subsidiary And Parent Of U.S. Biopharma Business
Brief: Grifols To Double Revolving Credit Facility To $2 Bln
Spanish stocks - Factors to watch on March 16
Spanish stocks - Factors to watch on March 13
Brief: Grifols Renews Deal With Ace Alzheimer Center Barcelona for AMBAR Program Expansion
MS cuts Grifols to 'equal-weight' amid revenue growth uncertainties
Europe Research Roundup: Bouygues, Man Group, Vallourec
Spanish stocks - Factors to watch on March 4
Grifols hits bottom of IBEX on weak 2026 revenue growth outlook
Spanish stocks - Factors to watch on Feb 27
Grifols sees core earnings rising by a quarter as it prioritises profitability (updated)
Grifols doubles net profit in 2025, driven by revenues
Brief: Grifols Sees 2026 Adjusted EBITDA Margin Above 25%
Brief: Grifols FY Adjusted EBITDA EUR 1,825 Million Vs. IBES Estimate EUR 1,808 Million
Spanish stocks - Factors to watch on Jan 16
Spanish stocks - Factors to watch on Dec 24
Brief: Grifols Gets FDA Approval For New Fibrinogen Concentrate, Fesiltytm
Brief: Grifols Gets EMA Approval For Manufacture And Selling Of Egyptian Plasma
Brief: Grifols Achieves Self-Sufficiency In Plasma-Derived Medicines In Egypt